Vivos Therapeutics Reports Q3 Revenue of $6.4 Million, Operating Loss Narrows 18%
Vivos Therapeutics reported third-quarter 2026 revenue of $6.4 million and a net loss of $2.0 million. Operating loss narrowed 18% year over year, while gross margin declined to 52% from 58%. The company said it regained compliance with Nasdaq’s stockholders’ equity requirement after completing its…